Blood microRNA testing in participants with suspicious low-dose CT findings: follow-up of the BioMILD lung cancer screening trial.
Boeri M, Sabia F, Ledda RE, Balbi M, Suatoni P, Segale M, Zanghì A, Cantarutti A, Rolli L, Valsecchi C, Corrao G, Marchianò A, Pastorino U, Sozzi G.
Boeri M, et al. Among authors: sabia f.
Lancet Reg Health Eur. 2024 Sep 16;46:101070. doi: 10.1016/j.lanepe.2024.101070. eCollection 2024 Nov.
Lancet Reg Health Eur. 2024.
PMID: 39319217
Free PMC article.